Table 1 Demographic characteristics, echocardiographic, clinical, and laboratory data of the study groups before the start of the furosemide injection

Gender^a

 Male/female

16/11

15-Dec

0.414

 Age^b (month)

6.11 ± 3.18

6.06 ± 3.19

0.954

 Weight^b (kg)

5.35 ± 1.52

5.24 ± 1.52

0.789

 Height^b (cm)

59.26 ± 6.77

60.70 ± 6.12

0.415

Underlying cardiac lesions^a

 VSD

6 (22.2)

9 (33.3)

0.18

 PDA

5 (18.5)

2 (7.4)

 VSD + ASD

9 (33.3)

12 (44.4)

 VSD + PDA

0

2 (7.4)

 ASD + PDA

5 (18.5)

2 (7.4)

 VSD + ASD + PDA

2 (7.4)

0

Echocardiography findings^a

 Left ventricular ejection fraction

47.67 ± 5.87

46.64 ± 7.32

0.578

Size of the lesions

 VSD (mm)

7.31 ± 2.09

8.19 ± 2.96

0.37

 ASD (mm)

5.44 ± 3.14

4.54 ± 2.40

0.403

 PDA (mm)

4.17 ± 1.47

5 ± 0.82

0.304

Precipitating factors of ADHF^a

 Acute bronchiolitis

10 (37)

10 (37)

0.775

 Pneumonia

10 (37)

9 (33.3)

 Gastroenteritis

7 (25.9)

6 (22.2)

 Incompliance to therapy

0

2 (7.2)

Preadmission oral furosemide ^b

 Number of patients

n = 22

n = 24

 Dose (mg/kg/day)

1.3 ± 0.25

1.38 ± 0.34

0.374

Clinical data^b

 HR (beat/min)

170.7 ± 6.2

171.6 ± 5.3

0.557

 RR (/min)

71.6 ± 5.9

73.4 ± 3.4

0.175

 SBP (mmHg)

109.2 ± 7.6

111.9 ± 6.4

0.158

 DBP (mmHg)

71.7 ± 3.7

70.1 ± 4.2

0.145

 SpO2 (%)

78.2 ± 3.6

77. 7 ± 4.4

0.692

Laboratory data^b

 Serum sodium (mmol/l)

137.9 ± 2.3

138.3 ± 2.6

0.541

 Serum potassium (mmol/l)

3.67 ± 0.41

3.71 ± 0.47

0.758

 Serum creatinine (mg/dl)

0.57 ± 0.12

0.60 ± 0.12

0.432